Extracapsular dissection for clinically benign parotid lumps: reduced morbidity without oncological compromise

M McGurk*,1, BL Thomas1 and AG Renehan2
1Salivary Gland Service, Department of Oral and Maxillofacial Surgery, Floor 23 Guy’s Tower, Guy’s Hospital, London Bridge, London SE1 9RT, UK;
2Department of Surgery, Christie Hospital NHS Trust, Manchester M20 4BX, UK

Previous studies have shown that extracapsular dissection (ECD) is an alternative approach to superficial parotidectomy (SP) for pleomorphic adenoma parotid tumours, associated with low recurrence rates equal to those following SP, but with significantly reduced morbidity. However, if a malignant tumour masquerades as a clinically benign lump, this approach may be inappropriate. This study addressed this question by analysing the outcome of 821 consecutive patients with parotid tumours treated at one centre over 40 years and with a median 12 (range 5–30) years follow-up. Tumours were classified as ‘simple’ (discrete, mobile, < 4 cm; n = 662) and ‘complex’ (deep, fixed, facial nerve palsy, ≥ 4 cm; n = 159). Among the ‘simple’ or clinically benign tumours, 503 patients underwent ECD; 159 patients underwent SP. In all, 32 (5%) clinically benign cases were subsequently revealed as malignant histologies (ECD, 12; SP, 20). For each group, 5- and 10-year cancer-specific survival rates were 100 and 98%, respectively. There were no differences in recurrence rates when subanalysed by surgical groups, but ECD was associated with significantly reduced morbidity (P < 0.001). This study demonstrates that ECD is a viable alternative to superficial parotidectomy for the majority of parotid tumours, associated with reduced morbidity without oncological compromise.

Keywords: parotid gland; extracapsular dissection; carcinoma; facial nerve palsy; survival

Parotid tumours are uncommon, with the majority presenting as discrete lumps arising within the superficial portion of the gland (Renehan et al, 1996). Conventional teaching prescribes removal of these tumours by superficial parotidectomy (SP), which encompasses facial nerve identification and en bloc removal of the superficial portion of the gland (Langdon, 2001). Extracapsular dissection (ECD) is an alternative approach to the removal of such lumps involving meticulous dissection immediately outside the tumour capsule while still preserving the facial nerve (Anderson, 1975; Gleave, 1995), and is distinct from enucleation. Based on the traditional view that many parotid tumours (notably pleomorphic adenomas) breach their capsule and so are theoretically at risk of recurrence from surgery close to the capsule (the ‘tumour bud’ concept) (Thackray and Lucas, 1974; Lawson, 1989, Naem et al, 1976), ECD has been received with caution. However, we have previously demonstrated in 475 patients with pleomorphic adenomas that ECD is associated with long-term low recurrence rates (< 2%) comparable with SP, but fewer complications (McGurk et al, 1996). Thus, in the practice of treating parotid pleomorphic adenomas, ECD reduces morbidity without oncological compromise. However, this procedure may not be appropriate for malignant tumours. The potential risk in ECD is encountering a malignant tumour masquerading as a benign lump – if this occurrence is common and the subsequent course of the cancer is adversely affected, it would prohibit the use of ECD as an alternative to SP for a simple parotid lump. This study addressed this question by analysing the outcome of 821 consecutive patients with parotid tumours treated at one centre over 40 years, and in particular, focuses on outcome when the histology was a carcinoma.

METHODS

Patients and pathology

Between 1952 and 1992, 821 patients with previously untreated epithelial parotid neoplasia were treated at the Christie Hospital, Manchester (Renehan et al, 1996, 1999; Gleave et al, 1979). The preoperative diagnosis was made on clinical grounds; fine needle aspiration cytology was not used. Tumours were classified by clinical criteria into (i) ‘simple’, which are discrete, mobile, and less than 4 cm in diameter (for the purpose of this paper, this is synonymous with ‘clinically benign’); and (ii) ‘complex’, which are greater than 4 cm and/or demonstrate fixity, facial nerve involvement, palpable cervical nodes, or deep lobe involvement (McGurk et al, 1995, 2001). For tumours with a malignant histology, simple tumours equated to AJCC Stage I disease. Complex tumours were not treated by ECD, and excluded from the analysis. The histological diagnoses were updated in the mid-1970s in line with the WHO classifications (Thackray and Sobin, 1972; Seifert and Sobin, 1991). Median follow-up was 12 (range 5–32) years.

Treatment

Among the ‘simple’ tumours, 503 patients underwent ECD, 159 patients underwent SP. The choice of technique was made on clinical criteria, namely mobility at surgery after raising the skin flap. This procedure has been described in detail elsewhere (Gleave, 1995). In this technique, the plane of dissection is within
a compartment of loose areolar tissue approximately 2–3 mm from the tumour. This contrasts sharply with enucleation, which breaches the capsule and removes the tumour within. Post-operative adjuvant radiotherapy (RT) (McGurk et al., 1996; Renihan et al., 1999) was used selectively, either for spillage of benign tumour or for those malignant tumours with a positive margin, spillage, adenoid cystic or high-grade carcinomas.

Statistical analysis

Comparisons of means were by Student’s t-test; proportions were compared by χ²-tests or Fisher’s exact test, where expected frequencies were less than five. Cancer-specific survival and recurrence rates were calculated by the Kaplan–Meier method and differences tested by log-rank (STATA version 7.0, College Station, CA, USA).

RESULTS

Basic characteristics

The baseline characteristics for the 821 tumours are outlined in Table 1. The majority (662 or 81%) presented as ‘simple’ lumps, of which only 32 or 5% proved to carcinomas. By contrast, two-thirds of ‘complex’ tumours had a malignant histology. The pattern of malignant histological types differed between ‘simple’ and ‘complex’ tumours: notably, two-thirds of ‘simple’ lumps with subsequent malignant histology were either acinic cell or low-grade mucoepidermoid carcinoma.

Survival and recurrence rates

In the 32 patients with ‘simple’ lumps, which proved to be carcinomas, 12 underwent ECD and 20 underwent SP. Following surgery, over half of these patients received radiotherapy (ECD, 7/12; SP, 12/20) — the indications are shown in Table 2. While these surgical groups were not randomly determined, the clinicopathological characteristics were broadly comparable (Table 3). The 5- and 10-year cancer-specific survival rates were 100 and 98%, respectively for ECD and SP (Figure 1A). Local recurrences developed in six cases (ECD, 1: SP, 5), with no statistical difference by log-rank testing between the two groups (Figure 1B). Only one of the six cancer recurrences occurred in a patient who had received both surgery and radiotherapy (Table 4); thus, radiotherapy per se may have been a confounding factor in determining recidivism.

Of the 630 patients with ‘simple’ lumps and benign histologies, there were 10 recurrences at 15 years. Eight recurrences occurred after 491 ECDs (1.7% at 15 years by life-table analysis); two recurrences occurred after 139 SPs (1.8% at 15 years by life-table analysis).

Morbidity

The complications by surgical groups and histological categories are shown in Table 5. Among the 630 patients with a ‘simple’ tumour and benign pathology, ECD was associated with significantly reduced morbidity compared with SP, including transient facial palsy (P < 0.001), Frey’s syndrome (P < 0.001), and aneurysm neopla (P < 0.001) (Table 5). Salivary fistulae developed without obvious causes in three patients treated by ECD.

Table 1 Characteristics of parotid tumours, Christie Hospital (1952–1992)

|                | Simple | Complex |
|----------------|--------|---------|
| Total number   | 662    | 159     |
| Median age (years) | 47 (5–87) | 58 (25–85) |
| Males          | 267 (40) | 83 (50) |
| Females        | 395     | 82      |
| Benign histology | 630 (95) | 50 (31) |
| Pleomorphic adenoma | 487     | 45      |
| Warthin’s tumour | 131     | 5       |
| Monomorphic adenomas | 12      | 0       |
| Malignant histology | 32 (5)  | 109 (69) |
| Acinic cell carcinoma | 7       | 6       |
| LG mucoepidermoid carcinoma | 13      | 11      |
| HG mucoepidermoid | —       | 3       |
| Basal cell adenocarcinoma | —      | 1       |
| Papillary cystadenocarcinoma | 2       | 2       |
| Mucinous adenocarcinoma | —     | 1       |
| Adenocarcinoma, NOS | —     | 16      |
| Adenoid cystic carcinoma | 5       | 28      |
| Epithelial–myoepithelial ca. | —     | 1       |
| Ca. ex-pleomorphic adenoma | 4      | 13      |
| Squamous cell carcinoma | —     | 7       |
| Undifferentiated carcinoma | 1     | 20      |

*pFor malignant tumours, ‘simple’ lumps are equivalent to AJCC Stage I disease. Values in parentheses are percentages unless otherwise indicated. See text for definitions of ‘simple’ and ‘complex’, NOS = not otherwise specified; ca. = carcinoma. LG = low-grade; HG = high-grade.

Table 2 Indications for postoperative radiotherapy among 19 patients with stage I cancers

|                           | Extracapsular dissection (n=7) | Superficial parotidectomy (n=12) |
|---------------------------|-------------------------------|----------------------------------|
| Positive tumour margin    | 2                             | 0                                |
| Close tumour margin       | 3                             | 7                                |
| Tumour spillage           | 0                             | 2                                |
| High-grade cancer         | 2                             | 3                                |
| Adenoid cystic carcinoma  | 1                             | 3                                |

For some tumours, there may have been more than one indication for postoperative radiotherapy.

Table 3 Clinicopathological characteristics of 32 stage I carcinomas

|                        | Extracapsular dissection (n=12) | Superficial parotidectomy (n=20) | P-value* |
|------------------------|----------------------------------|----------------------------------|----------|
| Age (mean) (s.d.)      | 44 (21)                          | 52 (22)                          | 0.33     |
| Male : female          | 5:7                              | 10:10                            |          |
| Size less than 2 cm    | 4 (33)                           | 5 (25)                           | 0.70     |
| Histology              |                                  |                                  |          |
| Mucoepidermoid carcinoma | 7 (58)                          | 6 (30)                           |          |
| Acinic cell carcinoma  | 1                               | 6 (30)                           |          |
| Adenoid cystic carcinoma | 1                             | 4 (20)                           |          |
| Other carcinomas       | 3 (25)                           | 4 (20)                           |          |
| Malignant grade        |                                  |                                  |          |
| Grade I                | 9 (75)                           | 13 (65)                          | 0.70     |
| Grade II               | 5 (40)                           | 3 (15)                           |          |
| Grade III              | 2 (15)                           | 3 (15)                           |          |
| Positive tumour margins| 2                               | 0                                | 1.00     |
| Close tumour margins   | 3 (25)                           | 8 (40)                           | 0.46     |
| Perineural invasion    | 0                               | 1                                |          |
| Tumour spillage        | 0                               | 2                                | 1.00     |

*Student’s t-test, χ², and Fisher’s exact tests as appropriate. Values in parentheses are percentages. s.d. = standard deviation.
but resolved spontaneously within 3 months. For the patients with 'simple' tumours and malignant histologies, complication rates were generally higher, but this was based on small patient numbers. There were no apparent differences between ECD and SP.

**DISCUSSION**

This study has demonstrated that the majority of parotid tumours present as a clinically benign lump, and of these, only 5% subsequently prove to be carcinomas. This study establishes ECD as a viable alternative surgical approach to superficial parotidectomy in such tumours, for it has the advantage of reduced morbidity without untoward effects on oncological outcome.

The advantages of this study were large numbers of patients treated with a similar surgical philosophy, and followed for a long period. Thus, we were able to show that out of 662 clinically benign parotid lumps, SP was avoided in 503 patients, and replaced with a more conservative procedure carrying significantly less morbidity. In adopting this conservative approach, there was a diagnostic error rate of 32/662, with 12 patients treated 'inappropriately' by ECD. The question was whether these 'errors' resulted in a poor outcome, but this was not the case. The authors accept that the 12 patients should ideally have been treated by some form of parotidectomy, and in such circumstances, seven patients may have avoided RT – these represent the penalty paid for saving 503 patients the need to undergo parotidectomy.

The merit of classifying discrete parotid lumps into 'simple' or 'complex' is confirmed in this study. Using clinical judgement alone, the assessment of 662 simple lumps ('benign tumours') was correct in 95% of the cases. Following a final step of clinical assessment at surgery, 12 of the 32 malignant tumours were removed by ECD rather than SP (a clinical diagnostic error rate of 1.8%). This equates to a test sensitivity of 93% and a positive predictive value of 95% (Altman and Bland, 1994). In theory, if clinical assessment is supplemented with fine needle aspiration cytology (McGurk and Hussain, 1997), these predictive values may increase.

Only 5% of clinically benign parotid tumours were carcinomas and notably two-thirds of these were low-grade cancers (acinic cell and low-grade mucoepidermoid carcinomas). Half required post-operative radiotherapy but this did not represent overtreatment of Stage I disease (Frankenthaler et al, 1991). Irrespective of the surgical approach, the long-term prognosis in this group was good. A similar experience was reported by Nnochiri et al (1990), who encountered 20 (4%) carcinomas unexpectedly in a series of 539 otherwise unremarkable parotid tumours. These tumours were treated surgically as nonmalignant lumps, yet subsequently followed a benign course.

As long-term low recurrence rates are now the norm for parotid pleomorphic adenomas, there is an emerging trend towards low morbidity surgery. Series employing either total parotidectomy or formal superficial parotidectomy report high rates of transient facial nerve palsy (15–70%) and Frey's syndrome (13–66%) (reviewed in Langdon, 2001). Recent studies have advocated a more conservative parotidectomy, partial superficial parotidectomy, and report lower transient facial nerve rates (20–33%) and Frey's syndrome rates (7–20%) (Yamashita et al, 1993; Helmus, 1997; Leverstein et al, 1997; Snow, 2001). Still lower rates of morbidity have been reported, following ECD (Anderson, 1975; Martis, 1983; Prichard et al, 1992) with 3–11% transient facial nerve palsy and 0–5% Frey's syndrome. The very low rates of gustatory sweating after ECD are presumably due to less disruption of the parotid tissue. ECD also avoids the unsightly complication of retromandibular depression frequently observed after superficial parotidectomy.

As the needs for reducing morbidity and maintaining facial aesthetics increase, ECD represents the current limit of conservative parotid surgery. A common feature of all minimally invasive therapies is that the technique leaves little room for error. With acceptance of these limitations, the findings of this study demonstrate that ECD is a scientifically valid and oncologically safe approach to the management of the clinically benign parotid lump.
Table 5 Complications after treatment of benign and malignant histologies

|                      | Benign histologies | Malignant histologies |
|----------------------|--------------------|-----------------------|
|                      | ECD (n = 491)      | SP (n = 139)          | P-value* |
| Facial nerve palsy   |                    |                      |          |
| Permanent            | 8 (1.6)            | 2 (1.4)              | NS       |
| Transient            | 48 (10)            | 45 (32)              | < 0.001  |
| Frey’s syndrome      | 25 (3)             | 45 (32)              | < 0.001  |
| Amputation neuroma   | 17 (3)             | 22 (16)              | < 0.001  |
| Salivary fistula     | 3 (0.6)            | 0                    | NS       |
|                      |                    |                      |          |
|                      | ECD (n = 12)       | SP (n = 20)          | P-value* |
|                      |                    |                      |          |
| Facial nerve palsy   |                    |                      |          |
| Permanent            | 1 (8)              | 3 (15)               | NS       |
| Transient            | 2 (10)             | 16 (15)              | NS       |
| Frey’s syndrome      | 2 (10)             | 3 (15)               | NS       |
| Amputation neuroma   | 2 (10)             | 4 (20)               | NS       |
| Salivary fistula     | 0                  | 0                    | NS       |

*χ² and Fisher’s exact tests as appropriate. Values in parentheses are percentages. NS = not significant.

REFERENCES

Altman DG, Bland JM (1994) Diagnostic tests. 1: sensitivity and specificity. BMJ 308: 1552
Anderson R (1975) Benign mixed tumours of the parotid gland. In Cancer of the Head and Neck, Proceedings of an International Symposium, Chamers RS, Jannsen de Limpens AMP, Jaques DA, Routledge RT (eds) Vol 37, pp 1555 – 1558. Amsterdam: Excerpta Medica
Frankenthaler RA, Luna MA, Lee SS, Ang KK, Byers RM, Guillaumondegu OM, Wolf P, Goepfert H (1991) Prognostic variables in parotid gland cancer. Arch Otolaryngol Head Neck Surg 117: 1251 – 1256
Gleave EN (1995) An alternative to superficial parotidectomy: extracapsular dissection. In Colour Atlas and Text of Salivary Glands: Diseases, Disorders and Surgery, de Burgh Norman J, McGurk M (eds) pp 165 – 172. London: Mosby-Wolf
Gleave EN, Whittaker JS, Nicholson A (1979) Salivary tumours - experience over thirty years. Clin Otolaryngol 4: 247 – 257
Helmus C (1997) Subtotal parotidectomy: a 10-year review (1985 to 1994). Laryngoscope 107: 1024 – 1027
Langdon J (2001) The significance of the tumour capsule in pleomorphic adenoma: the changing face of conventional principles. In Controversies in the Management of Salivary Gland Disease, McGurk M, Renehan AG (eds) pp 67 – 73. Oxford: Oxford University Press
Lawson HH (1989) Capsular penetration and perforation in pleomorphic adenoma of the parotid salivary gland. Br J Surg 76: 594 – 596
Leverstein H, van der Wal JE, Tiwari RM, van der Waal I, Snow GB (1997) Surgical management of 246 previously untreated pleomorphic adenomas of the parotid gland. Br J Surg 84: 399 – 403
McGurk M, Drage N (2001) Investigation of salivary gland lumps: clinical evaluation with a selective approach to the use of imaging and fine needle aspiration cytology. In Controversies in the Management of Salivary Gland Disease, McGurk M, Renehan AG (eds) pp 35 – 43. Oxford: Oxford University Press
McGurk M, Hussain K (1997) Role of fine needle aspiration cytology in the management of the discrete parotid lump. Ann R Coll Surg Engl 79: 198 – 202
McGurk M, Renehan A, Gleave EN, Hancock BD (1996) Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas. Br J Surg 83: 1747 – 1749
McGurk M, Williams BG, Calman F (1993) A clinical approach to malignant tumours. In Colour Atlas and Text of Salivary Glands: Diseases, Disorders and Surgery, de Burgh Norman J, McGurk M (eds) pp 181 – 196. London: Mosby-Wolf
Martis C (1983) Parotid benign tumors: comments on surgical treatment of 263 cases. Int J Oral Surg 12: 211 – 220
Naeim F, Forsberg MI, Waisman J, Coulson WF (1976) Mixed tumours of the salivary glands. Arch Pathol Lab Med 100: 271 – 275
Nocchi CC, Watkin T, Hobsley M (1990) Unremarkable parotid tumours that prove to be malignant. Br J Surg 77: 917 – 918
Prichard AJ, Barton RP, Narula AA (1992) Complications of superficial parotidectomy versus extracapsular lumpectomy in the treatment of benign parotid lesions. J Roy Coll Surg Edinburgh 37: 155 – 158
Renehan A, Gleave EN, Hancock BD, Smith P, McGurk M (1996) Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Br J Surg 83: 1750 – 1754
Renehan A, Gleave EN, Slevin NJ, McGurk M (1999) Clinico-pathological and treatment-related factors influencing survival in parotid cancer. Br J Cancer 80: 1296 – 1300
Seifert G, Sobin LH (1991) Histological Typing of Salivary Gland Tumours, 2nd edn. Berlin: Springer-Verlag
Snow G (2001) The surgical approaches to the treatment of parotid pleomorphic adenomas. In Controversies in the Management of Salivary Gland Disease, McGurk M, Renehan AG (eds) pp 57 – 66. Oxford: Oxford University Press
Thackray AC, Sobin LH (1972) Tumours of the major salivary glands. In Histological Typing of Salivary Gland Tumours, 2nd series, Fascicle 10, p 35, Washington: AFIP
Thackray AC, Lucas RB (1974) Tumours of the major salivary glands. In Atlas of Tumour Pathology, 2nd series, Fascicle 10, p 35, Washington: AFIP
Thackray AC, de Burgh Norman J, McGurk M (eds) pp 165 – 211. London: Mosby-Wolf
Yamashita T, Tomoda K, Kumazawa T (1993) The usefulness of partial capsular surgery for benign parotid lumps. A retrospective study of 306 cases. Acta Otolaryngol Suppl Stockh 500: 113 – 116